查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1496012

全球黄斑部病变检测与治疗市场：2024-2029 年预测

Global Macular Degeneration Testing and Therapeutics Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 100 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

黄斑部病变检测和治疗市场预计将从 2022 年的 118.32 亿美元增至 2029 年的 149.59 亿美元，预测期内复合年增长率为 3.42%。

黄斑部病变检测和治疗是针对这种常见眼科疾病的诊断和治疗方法，这种疾病会影响黄斑，黄斑部是视网膜的中央部分，负责敏锐的中央视力。黄斑部病变有两种主要类型：干性（萎缩性）和湿性（新生血管性或渗出性）。检验包括视力检查、散瞳验光、萤光血管造影术、光同调断层扫瞄(OCT) 和基因检测。

黄斑部病变检测和治疗市场包括旨在检测、监测和提供有效治疗方案的诊断工具、药品、补充品和医疗设备。诊断工具包括OCT机、眼底摄影机、萤光血管造影术系统、抗VEGF药物、补充品、眼内植入、低视力辅助器具、基因检测服务等。人口老化、诊断影像技术的进步以及对新治疗方法的持续研究正在推动市场发展。

市场驱动因素：

  • 随着研究和开发活性化，黄斑部病变检测和治疗市场预计将成长。

扩大研发力度和增加临床试验是产业成长的关键驱动力。研究和开发活动预计将推动黄斑部病变检测和治疗行业的发展。这包括扩大创造性的治疗方法，包括高品质的基因疗法、干细胞疗法和联合疗法。发现的治疗进展和生物标记的进步正在促进早期检测和个人化治疗。先进的药物输送框架正在开发中，包括新配方和缓释性植入。

此外，临床试验也已开始，以确保新药和治疗方法的商业化。这些努力预计将导致黄斑部病变新药获得监管部门的核准和商业化。例如，2022年11月，专注于基因治疗药物的临床阶段生物技术公司4D Molecular Therapeutics宣布，专注于基因治疗药物的临床阶段生物技术公司4D Molecular Therapeutics, Inc.宣布4D Molecular Therapeutics、 Inc.是一家专门从事基因治疗药物的临床阶段生物技术公司，宣布推出用于治疗湿性老龄化黄斑部病变（AMD）的玻璃体内4D-150 I/II期药物。 。

  • 视网膜疾病的日益普及预计将推动黄斑部病变检测和治疗市场的成长。

由于老龄化黄斑部病变(AMD) 的盛行率不断增加，黄斑部病变检测和治疗行业正在不断扩大，老年黄斑部病变是视力障碍的根本原因，尤其是在发展中人群中。促成这项进展的因素包括世界人口老化、导致营养不良的不良饮食习惯、肥胖、吸烟和饮酒等生活习惯、OCT等经验技术的进步以及眼部健康和筛检的进步。性的认识。

视网膜疾病的增加趋势正在促进产业的发展。例如，《英国眼科杂誌》2020 年 8 月的一项研究指出，AMD 是欧洲视力障碍和丧失的主要原因。欧洲约有6,700万人受到AMD的影响，由于世界老年人口的扩大，预计到2050年这数字将大幅增加至15%。这些资料凸显了受视网膜疾病影响的人数不断增加，特别是黄斑部病变治疗的需求不断增长。

北美地区预计将占据市场占有率。

北美市场参与企业面临着多种因素，包括老年人口的增加和老龄化黄斑部病变的普遍存在，以及主要行业参与者的进入以及透过市场参与企业和学术研究机构之间的合作伙伴关係扩大研发活动。例如，2020 年 8 月发表在《自然医学》上的一项研究发现，如果 AMD 患者感染了 SARS-CoV-2，他们更有可能出现严重的併发症，包括需要氧疗，这一点已经很明确，可能会危及生命。

先进的医疗系统、创新技术的研究、医疗投资的增加、政府活动、患者意识和学术研究促进了黄斑部病变检测和治疗产业的发展。政府措施、政策和临床试验可以为AMD的早期检测和控制提供支援。总的来说，这些因素将有助于未来几年北美现代治疗方法的进步和商业化。

美国黄斑部病变基金会 (AMDF) 发布此资料是为了提醒 AMD 患者和眼部保健专业人员注意潜在风险。 AMD 是全球不可逆视力障碍和视觉障碍的主要原因，并为该行业的成长做出了贡献。根据加拿大眼科学会2021年2月的讯息，湿性AMD是65岁以上族群视力丧失的重要原因之一。此外，根据加拿大大型企业联合会的讯息，评估视力丧失的费用预计将从 2007 年的 158 亿加元跃升至 2032 年的 303 亿加元。

市场发展：

  • 2024 年 3 月 - REGENXBIO 宣布一项 I/IIa 期研究，评估 ABBV-RGX-314 作为湿性AMD的一次性基因疗法。这项研究发现，这种治疗有可能成为标准治疗选择，维持长期视力健康，并克服长期注射抗 VEGF 治疗湿性AMD的临床挑战。
  • 2023 年 8 月 - 加州大学戴维斯分校眼科中心使用实验性基因疗法治疗湿性老龄化黄斑部病变。该治疗是评估 ABBV-RGX-314 有效性和安全性的 3 期临床试验的一部分，也是参与该试验的 93 个美国站点之一。
  • 2022 年 11 月 - IVERIC Bio, Inc. 已开始向美国食品药物管理局(FDA) 提交新药认证申请 (NDA) 的初始部分，用于 avacincapad pegol，这是一种新的在临床实验补体 C5 抑制剂。
  • 2022 年 11 月 - 欧盟委员会授予欧洲第三种雷珠单抗生物相似药 Ximluci 的营销核准。它由 STADA Arzneimittel 和 Xbrane Biopharma 共同开发，将于 2023 年初上市。

公司产品

  • Lee Numbers(R) 低视力手册 - Lee Numbers(R) 低视力手册是 Goodlight 公司的产品，专为测试严重视力障碍儿童和个人而设计，涵盖远端视力和近距离视力线尺寸。它们可以单独购买，也可以成套购买，其中包括儿童和成人铰接眼镜。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球黄斑部病变检测与治疗市场：按类型

  • 介绍
  • 萎缩型
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 渗出型
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章全球黄斑部病变检测与治疗市场：按地区

  • 介绍
  • 北美洲
    • 按类型
    • 按国家/地区
  • 南美洲
    • 按类型
    • 按国家/地区
  • 欧洲
    • 按类型
    • 按国家/地区
  • 中东/非洲
    • 按类型
    • 按国家/地区
  • 亚太地区
    • 按类型
    • 按国家/地区

第七章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第八章 公司简介

  • Good-Lite Company
  • Leica Microsystems
  • Optovue, Inc
  • Heidelberg Engineering GmbH
  • Topcon
  • Nano Retina
  • Macuhealth
  • LumiThera, Inc
  • Ellex Medical Lasers
  • Quantel Medical
简介目录
Product Code: KSI061612157

The global macular degeneration testing and therapeutics market is anticipated to expand at a CAGR of 3.42% amid the projected period to reach US$14.959 billion by 2029, from US$11.832 billion in 2022.

Macular degeneration testing and therapeutics are diagnostic methods and treatment approaches for the common eye condition, which affects the macula, the central part of the retina responsible for sharp, central vision. There are two main types of macular degeneration: dry (atrophic) and wet (neovascular or exudative). Tests include visual acuity tests, dilated eye exams, fluorescein angiography, optical coherence tomography (OCT), and genetic testing.

The market for macular degeneration testing and therapeutics includes diagnostic tools, pharmaceuticals, supplements, and medical devices designed to detect, monitor, and provide effective treatment options. Diagnostic tools include OCT machines, fundus cameras, fluorescein angiography systems, anti-VEGF drugs, supplements, intraocular implants, low vision aids, and genetic testing services. The market is driven by an aging population, advances in diagnostic imaging technology, and ongoing research into novel therapeutic approaches.

Market Drivers:

  • Increasing research and development is expected to surge the macular degeneration testing and therapeutics market growth.

Expanding R&D endeavors and a rise in clinical trials characterized critical drivers of industry growth. R&D practices are anticipated to boost the macular degeneration testing and therapeutics industry. This incorporates expanding inventive therapeutic approaches, quality gene treatments, stem cell treatments, and combination treatments. Progressions in discovery and advancements in biomarkers empower early detection and personalized treatment. Progressed medication delivery frameworks are being created, involving novel formulations and sustained-release implants.

Additionally, Clinical trials are being started to guarantee the commercialization of new medicines and therapies These endeavors are anticipated to lead to regulatory bodies endorsements and the commercialization of new medications for macular degeneration. For instance, in November 2022, 4D Molecular Therapeutics, Inc., a clinical-stage biotechnology company specializing in focused on genetic medications, reported interim clinical discoveries from the Phase I/II trial of intravitreal 4D-150 for wet age-related macular degeneration (AMD).

  • The rising predominance of retinal disorders is anticipated to propel the macular degeneration testing and therapeutics market growth.

The macular degeneration testing and therapeutics industry is expanding due to the increasing prevalence of age-related macular degeneration (AMD), a basic cause of vision inability, particularly inside the developing masses. Factors contributing to this advancement incorporate the worldwide aging populace, lifestyle habits such as poor diet causing malnutrition, obese population, smoking, and drinking, strides in demonstrative technological advancements such as OCT, and extended awareness around the significance of eye wellbeing and screening programs.

The growing predominance of retinal disorders is contributing to industry development. For instance, research in August 2020 by the British Journal of Ophthalmology stated that AMD is the primary factor of visual incapacity and visual loss in Europe. Around 67 million individuals in Europe are influenced by AMD, and this figure is expected to increase significantly to 15% by 2050 due to the expanding elderly population globally. These statistical data emphasize the rising number of people affected by retinal diseases, which particularly interfaces with the extended request for macular degeneration treatment and in this way drives market extension.

The North American area is expected to dominate the market share.

Market expansion in North America is driven by different components, like the increasing senior population and the predominance of age-related macular degeneration, in conjunction with the participation of key industry players and expanded R&D activities with the partnership of market players and academic research institutes. For instance, research published in Nature Medicine in August 2020 revealed that individuals with AMD who contract SARS-CoV-2 confront a higher chance of serious complications, involving requiring supplemental oxygen or can be fatal too.

The country's progressed healthcare framework, investigations for innovative technology, rising healthcare investment, government activities, awareness among patients, and academic research contribute to the macular degeneration testing and therapeutics industry expansion. Government initiatives and policies as well as clinical trials can offer assistance to identify and control AMD at an early stage. Generally, these components contribute to the advancement and commercialization of modern treatments in North America in the years ahead.

The American Macular Degeneration Foundation (AMDF) dispersed this data to alert both AMD patients and eye care experts about the potential risks involved. AMD is a driving main cause of irreversible visual impairment and visual disability universally, contributing to industry growth. According to information from the Canadian Ophthalmological Society from February 2021, wet AMD positions among the essential causes of vision loss in people aged over 65. Moreover, information from the Conference Board of Canada expressed that the evaluated cost of vision loss is projected to surge up to $30.3 billion by 2032 from $15.8 billion in the year 2007.

Market Developments:

  • March 2024- REGENXBIO published a Phase I/IIa study evaluating ABBV-RGX-314 as a one-time gene therapy for wet AMD. The study found that the treatment could become a standard-of-care option, sustaining vision health long term and overcoming the clinical challenges of managing wet AMD due to chronic anti-VEGF injections. Long-term follow-up data showed stable or improved vision for up to four years.
  • August 2023- UC Davis Eye Center used experimental gene therapy for wet age-related macular degeneration, marking the first time the center employed such a treatment. The treatment is part of a stage 3 clinical trial assessing the adequacy and security of ABBV-RGX-314, one of 93 U.S. destinations participating in the experiment.
  • November 2022- IVERIC Bio, Inc. initiated the submission of the initial portion of its New Drug Application (NDA) to the US Food and Drug Administration (FDA) for avacincaptad pegol, a new investigational inhibitor of complement C5. This accommodation marks the start of a rolling survey to prepare for the treatment of geographic atrophy (GA) auxiliary to Age-Related Macular Degeneration (AMD).
  • November 2022- Marketing authorization was granted by the European Commission for Ximluci, the third biosimilar of ranibizumab, to be approved in the European Union. Created through the collaboration between STADA Arzneimittel and Xbrane Biopharma, the product was discharged to market in early 2023.

Company Product:

  • LEA NUMBERS(R) Low Vision Book- The LEA NUMBERS(R) Low Vision book is a product by Good-Lite Company and is designed for testing severely visually impaired children and adults, covering distance and near vision line sizes. It can be purchased individually or as part of a set, including pediatric and adult occluding glasses.

Market Segmentation:

Global Macular Degeneration Testing and Therapeutics Market is segmented and analyzed as below:

By Type

  • Dry
  • Wet

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL MACULAR DEGENERATION TESTING AND THERAPEUTICS MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Dry
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Wet
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness

6. GLOBAL MACULAR DEGENERATION TESTING AND THERAPEUTICS MARKET BY GEOGRAPHY

  • 6.1. Introduction
  • 6.2. North America
    • 6.2.1. By Type
    • 6.2.2. By Country
      • 6.2.2.1. USA
        • 6.2.2.1.1. Market Opportunities and Trends
        • 6.2.2.1.2. Growth Prospects
      • 6.2.2.2. Canada
        • 6.2.2.2.1. Market Opportunities and Trends
        • 6.2.2.2.2. Growth Prospects
      • 6.2.2.3. Mexico
        • 6.2.2.3.1. Market Opportunities and Trends
        • 6.2.2.3.2. Growth Prospects
  • 6.3. South America
    • 6.3.1. By Type
    • 6.3.2. By Country
      • 6.3.2.1. Brazil
        • 6.3.2.1.1. Market Opportunities and Trends
        • 6.3.2.1.2. Growth Prospects
      • 6.3.2.2. Argentina
        • 6.3.2.2.1. Market Opportunities and Trends
        • 6.3.2.2.2. Growth Prospects
      • 6.3.2.3. Others
        • 6.3.2.3.1. Market Opportunities and Trends
        • 6.3.2.3.2. Growth Prospects
  • 6.4. Europe
    • 6.4.1. By Type
    • 6.4.2. By Country
      • 6.4.2.1. United Kingdom
        • 6.4.2.1.1. Market Opportunities and Trends
        • 6.4.2.1.2. Growth Prospects
      • 6.4.2.2. Germany
        • 6.4.2.2.1. Market Opportunities and Trends
        • 6.4.2.2.2. Growth Prospects
      • 6.4.2.3. France
        • 6.4.2.3.1. Market Opportunities and Trends
        • 6.4.2.3.2. Growth Prospects
      • 6.4.2.4. Italy
        • 6.4.2.4.1. Market Opportunities and Trends
        • 6.4.2.4.2. Growth Prospects
      • 6.4.2.5. Others
        • 6.4.2.5.1. Market Opportunities and Trends
        • 6.4.2.5.2. Growth Prospects
  • 6.5. Middle East and Africa
    • 6.5.1. By Type
    • 6.5.2. By Country
      • 6.5.2.1. Saudi Arabia
        • 6.5.2.1.1. Market Opportunities and Trends
        • 6.5.2.1.2. Growth Prospects
      • 6.5.2.2. Israel
        • 6.5.2.2.1. Market Opportunities and Trends
        • 6.5.2.2.2. Growth Prospects
      • 6.5.2.3. Others
        • 6.5.2.3.1. Market Opportunities and Trends
        • 6.5.2.3.2. Growth Prospects
  • 6.6. Asia Pacific
    • 6.6.1. By Type
    • 6.6.2. By Country
      • 6.6.2.1. China
        • 6.6.2.1.1. Market Opportunities and Trends
        • 6.6.2.1.2. Growth Prospects
      • 6.6.2.2. Japan
        • 6.6.2.2.1. Market Opportunities and Trends
        • 6.6.2.2.2. Growth Prospects
      • 6.6.2.3. India
        • 6.6.2.3.1. Market Opportunities and Trends
        • 6.6.2.3.2. Growth Prospects
      • 6.6.2.4. South Korea
        • 6.6.2.4.1. Market Opportunities and Trends
        • 6.6.2.4.2. Growth Prospects
      • 6.6.2.5. Indonesia
        • 6.6.2.5.1. Market Opportunities and Trends
        • 6.6.2.5.2. Growth Prospects
      • 6.6.2.6. Thailand
        • 6.6.2.6.1. Market Opportunities and Trends
        • 6.6.2.6.2. Growth Prospects
      • 6.6.2.7. Taiwan
        • 6.6.2.7.1. Market Opportunities and Trends
        • 6.6.2.7.2. Growth Prospects
      • 6.6.2.8. Others
        • 6.6.2.8.1. Market Opportunities and Trends
        • 6.6.2.8.2. Growth Prospects

7. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 7.1. Major Players and Strategy Analysis
  • 7.2. Market Share Analysis
  • 7.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 7.4. Competitive Dashboard

8. COMPANY PROFILES

  • 8.1. Good-Lite Company
  • 8.2. Leica Microsystems
  • 8.3. Optovue, Inc
  • 8.4. Heidelberg Engineering GmbH
  • 8.5. Topcon
  • 8.6. Nano Retina
  • 8.7. Macuhealth
  • 8.8. LumiThera, Inc
  • 8.9. Ellex Medical Lasers
  • 8.10. Quantel Medical